CRBU: Caribou Bio Net earnings per share (EPS TTM)

Public company logo of Caribou Biosciences Inc. (CRBU)

The fundamental TTM net income per share for Caribou Biosciences (CRBU) on GURU.Markets reflects business development within an autonomous product cycle, where the -1.03 mark records this metric. Caribou Biosciences develops unique CRISPR platforms to combat cancer, securing patent protection and capital from partners. However, a lack of sales leaves the company dependent on external financing, as the research stage precludes predictable cash flows.

CRBU (Caribou Biosciences) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/18/2026

Caribou Biosciences - analytical breakdowns and key metrics (CRBU)

General company analysis:cariboubio.com (CRBU)
Mass-produced product of Caribou Biosciences, Inc

This indicator reflects the annual net profit of Caribou Biosciences (CRBU) distributed per share, allowing for an assessment of the actual return on capital regardless of the total issuance volume. By analyzing the TTM net income per share of Caribou Biosciences (CRBU), an investor can see how CRISPR development costs in partnership with AbbVie impact the financial result, determining the risk of purchasing the asset at a local peak in profitability.